Optimizing Molecular Profiling for Decision-Making in mCRPC: Integrating Tissue Biopsy, Liquid Biopsy and Re-Biopsy Through a Broad Multidisciplinary Approach

Molecular profiling is essential for therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC), but implementation is limited by tissue availability, bone-predominant disease, tumor heterogeneity and organizational barriers. This conference report summarizes a multidisciplinary educational meeting held in Naples, Italy, on 12 May 2026. The program combined presentations, moderated multidisciplinary discussions and two exploratory audience polls addressing nine questions. Survey results were summarized descriptively to contextualize the discussion. Molecular profiling was viewed as an integrated diagnostic pathway rather than an isolated laboratory test. Successful implementation requires timely planning, involvement of interventional radiologists in the multidisciplinary selection among nodal, visceral, osseous and other metastatic biopsy targets, optimized tissue acquisition and processing, early pathological assessment of specimen adequacy and coordinated interpretation of molecular findings. Archival tissue, newly acquired metastatic tissue, liquid biopsy and re-biopsy were considered complementary strategies to optimize profiling according to disease characteristics, specimen availability, prior results and clinical needs. Non-informative results should prompt reassessment and consideration of an alternative sampling strategy, consistent with diagnostic persistence. Implementation depends on multidisciplinary collaboration and adaptable pathways addressing access, geographic equity and resource sustainability. This evidence-informed framework aims to support harmonization of molecular profiling pathways in mCRPC without yet constituting recommendations or formal consensus.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2026-11-18
DOI
https://doi.org/10.3390/curroncol33110713
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimizing Molecular Profiling for Decision-Making in mCRPC: Integrating Tissue Biopsy, Liquid Biopsy and Re-Biopsy Through a Broad Multidisciplinary Approach

Francesco Fiore, Sabrina Rossetti, Lorena Incorvaia, Sergio Bracarda et al.
4 links
Current Oncology
Prostate Cancer Treatment and Research
article

Optimizing Molecular Profiling for Decision-Making in mCRPC: Integrating Tissue Biopsy, Liquid Biopsy and Re-Biopsy Through a Broad Multidisciplinary Approach

Francesco Fiore, Sabrina Rossetti, Lorena Incorvaia, Sergio Bracarda, Agostino Inzerillo, Alessia Cimadamore, Francesco Pepe, Sandro Pignata
article en

Abstract

Molecular profiling is essential for therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC), but implementation is limited by tissue availability, bone-predominant disease, tumor heterogeneity and organizational barriers. This conference report summarizes a multidisciplinary educational meeting held in Naples, Italy, on 12 May 2026. The program combined presentations, moderated multidisciplinary discussions and two exploratory audience polls addressing nine questions. Survey results were summarized descriptively to contextualize the discussion. Molecular profiling was viewed as an integrated diagnostic pathway rather than an isolated laboratory test. Successful implementation requires timely planning, involvement of interventional radiologists in the multidisciplinary selection among nodal, visceral, osseous and other metastatic biopsy targets, optimized tissue acquisition and processing, early pathological assessment of specimen adequacy and coordinated interpretation of molecular findings. Archival tissue, newly acquired metastatic tissue, liquid biopsy and re-biopsy were considered complementary strategies to optimize profiling according to disease characteristics, specimen availability, prior results and clinical needs. Non-informative results should prompt reassessment and consideration of an alternative sampling strategy, consistent with diagnostic persistence. Implementation depends on multidisciplinary collaboration and adaptable pathways addressing access, geographic equity and resource sustainability. This evidence-informed framework aims to support harmonization of molecular profiling pathways in mCRPC without yet constituting recommendations or formal consensus.

Current OncologyVol. 33(11)
University of Udine (IT), Ospedale Sacro Cuore Don Calabria (IT), Federico II University Hospital (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT), University of Naples Federico II (IT), University of Palermo (IT)
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon